Search

everythinglearnresearchcommunity

for

Search:↓

A user's experience with using 5AR inhibitors (Finasteride and Dutasteride) in combination with Minoxidil foam and microneedling, which resulted in substantial improvements to their crown density and hairline, despite high systemic levels of testosterone and dihydrotestosterone.

A 20 year old male discussing his hair loss regimen, which includes using topical dutasteride, rogaine, RU58841, minoxidil and Avodart pills as well as scalp massage, stabbing head with steak knife, counting shed hairs under a hair net and sending them to a lab for analysis. Suggestions from other users include scalping method and switching to saw palmetto and zinc supplements.

A user is experiencing hairline recession and has started using RU58841, applying it to the temples. They are seeking advice on the appropriate dosage for this specific area.

Alfatradiol is considered safe but less effective than finasteride for hair loss. One user reported subtle regrowth using alfatradiol with finasteride and minoxidil, while another found alfatradiol ineffective.

RU58841 is discussed as a topical anti-androgen for hair loss, but its effectiveness and safety are not well-documented, leading to mixed opinions and experiences among users. Some combine it with finasteride, but concerns about side effects and lack of FDA approval limit its popularity.

Creatine may affect hair loss by reducing PGE2 levels, which could influence hair growth. The discussion highlights the need for more research on this potential mechanism.

A 30-year-old man with hairline recession is considering using 1% Clascoterone cream on his hairline while awaiting a 5% Breezula product. He has been using oral Minoxidil for four years but stopped using Finasteride due to side effects.

A user experienced increased testosterone and estradiol levels after starting finasteride/dutasteride and is asking if these levels will return to normal over time. The conversation focuses on whether these changes are temporary.

The conversation discusses a clinical trial for Setipiprant in the US, starting June 29th, with eligibility excluding recent users of minoxidil or finasteride. It encourages informed decision-making before signing up.

The conversation discusses a 20-year-old transgender female's one-year experience with hair loss treatments, including Estradiol HRT, oral Finasteride, Bicalutamide, and Cyproterone. Specific treatments used for hair loss are oral Finasteride and potentially Estradiol as part of hormone replacement therapy.